Alcuronium Chloride | 15180-03-7

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 马钱子生物碱
• 英文名称: Alcuronium Chloride
• 英文别名: (2E)-2-[(1S,9Z,11S,13S,14R,17S,25Z,27S,30R,33S,35S,36S,38E)-38-(2-hydroxyethylidene)-14,30-bis(prop-2-enyl)-8,24-diaza-14,30-diazoniaundecacyclo[25.5.2.211,14.11,26.110,17.02,7.013,17.018,23.030,33.08,35.024,36]octatriaconta-2,4,6,9,18,20,22,25-octaen-28-ylidene]ethanol;dichloride
• CAS: 15180-03-7
• 化学式: C44H50Cl2N4O2
• 分子量: 737.8
• InChiKey: CPYGBGOXCJJJGC-GKLGUMFISA-L

计算性质

• 辛醇/水分配系数(LogP)：
  -0.52
• 重原子数：
  52
• 可旋转键数：
  6
• 环数：
  11.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  46.9
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  3,4-二羟基苯甲酸乙酯 在 4-二甲氨基吡啶 、 二氧化碳 、 silver fluoride 作用下， 以 二氯甲烷 、 丙酮 为溶剂， 反应 20.5h， 生成 Alcuronium Chloride
  参考文献：
  名称：

  用氟化银（I）对硫代苯并二恶唑进行氟硫磺化。

  摘要：

  二氟苯并二恶唑是在药物和农用化学品中都发现的重要官能团。HF和强氧化剂的典型氟化条件挑战了该官能团的后期引入。在这里，我们证明了可以从儿茶酚中分两步制备一系列二氟苯并二恶唑，方法是将其转化为硫代苯并二恶唑，然后用氟化银（I）进行脱硫氟化。这些温和的反应条件可与多种官能团兼容，并能够使用一系列官能化的二氟苯并二恶唑。

  DOI：

  10.1021/acs.joc.0c01729

文献信息

• SUBSTITUTED BIPIPERIDINYL DERIVATIVES
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：US20160318866A1

  公开（公告）日：2016-11-03

  The invention relates to novel substituted bipiperidinyl derivatives, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of diabetic microangiopathies, diabetic ulcers on the extremities, in particular for promoting wound healing of diabetic foot ulcers, diabetic heart failure, diabetic coronary microvascular heart disorders, peripheral and cardiac vascular disorders, thromboembolic disorders and ischaemias, peripheral circulatory disturbances, Raynaud's phenomenon, CREST syndrome, microcirculatory disturbances, intermittent claudication, and peripheral and autonomous neuropathies.

  该发明涉及新型取代的双哌啶衍生物，涉及它们的制备方法，涉及它们用于治疗和/或预防疾病以及用于制备治疗和/或预防疾病的药物的用途，特别是用于治疗和/或预防糖尿病微血管病变、四肢糖尿病溃疡，特别是促进糖尿病足溃疡愈合、糖尿病心力衰竭、糖尿病冠状微血管心脏疾病、外周和心脏血管疾病、血栓栓塞疾病和缺血、外周循环障碍、雷诺现象、CREST综合征、微循环障碍、间歇性跛行以及外周和自主神经病变的治疗和/或预防。
• SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF
  申请人：Brüggemeier Ulf

  公开号：US20100261771A1

  公开（公告）日：2010-10-14

  The present application relates to new, substituted 2-acetamido-5-aryl-1,2,4-triazolones, to processes for preparing them, to their use alone or in combinations for the treatment and/or prevention of diseases and also to their use for the production of medicaments for the treatment and/or prevention of diseases, more particularly for the treatment and/or prevention of cardiovascular disorders.

  本申请涉及新的、取代的2-乙酰胺基-5-芳基-1,2,4-三唑酮，以及制备它们的方法，它们单独或组合用于治疗和/或预防疾病，以及它们用于生产用于治疗和/或预防疾病的药物，更具体地用于治疗和/或预防心血管疾病。
• BISARYL-BONDED ARYLTRIAZOLONES AND USE THEREOF
  申请人：Furstner Chantal

  公开号：US20130190330A1

  公开（公告）日：2013-07-25

  The present application relates to novel bisaryl-linked 5-aryl-1,2,4-triazolone derivatives, to processes for preparing them, to their use alone or in combinations for the treatment and/or prevention of diseases and also to their use for the production of medicaments for the treatment and/or prevention of diseases, more particularly for the treatment and/or prevention of cardiovascular disorders.

  本申请涉及新型的双芳基连接的5-芳基-1,2,4-三唑啉酮衍生物，涉及制备它们的方法，涉及它们单独或组合用于治疗和/或预防疾病，以及涉及它们用于生产用于治疗和/或预防疾病的药物，尤其是用于治疗和/或预防心血管疾病的药物。
• SUBSTITUTED FUROPYRIMIDINES AND USE THEREOF
  申请人：Lampe Thomas

  公开号：US20110166163A1

  公开（公告）日：2011-07-07

  The present application relates to novel substituted furopyrimidine derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prophylaxis of cardiovascular diseases.

  本申请涉及新型的取代呋喃嘧啶衍生物，及其制备过程，用于治疗和/或预防疾病，以及用于制备用于治疗和/或预防疾病的药物，特别是用于治疗和/或预防心血管疾病。
• SUBSTITUTED PYRROLOTRIAZINES AND THEIR USE
  申请人：Lampe Thomas

  公开号：US20110028479A1

  公开（公告）日：2011-02-03

  The present application relates to new, substituted pyrrolo[2,1-f][1,2,4]triazine derivatives of the formula (I) as prostacyclin (PGI 2 ) IP receptor activators for the treatment and/or prophylaxis of cardiovascular disorders.

  本申请涉及新的、取代的吡咯并[2,1-f][1,2,4]三嗪衍生物，其化学式为(I)，作为前列环素（PGI2）IP受体激动剂，用于治疗和/或预防心血管疾病。